Tocilizumab in severe COVID-19.
作者信息
Lucio Liberato Nicola, De Monte Andrea, Caravella Giuseppe
机构信息
Department of Medicine, ASST Melegnano e della Martesana, Vizzolo Predabissi (MI), Italy.
Department of Oncology, ASST Melegnano e della Martesana, Vizzolo Predabissi (MI), Italy.
出版信息
Arch Med Sci. 2020 Jul 16;16(6):1457-1458. doi: 10.5114/aoms.2020.97411. eCollection 2020.
Abstract
摘要
相似文献
1
Tocilizumab in severe COVID-19.托珠单抗治疗重症新型冠状病毒肺炎
Arch Med Sci. 2020 Jul 16;16(6):1457-1458. doi: 10.5114/aoms.2020.97411. eCollection 2020.
2
Tocilizumab and liver injury in patients with COVID-19.托珠单抗与新冠病毒肺炎患者的肝损伤
Therap Adv Gastroenterol. 2020 Oct 7;13:1756284820959183. doi: 10.1177/1756284820959183. eCollection 2020.
3
Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.托珠单抗治疗重型和危重型新型冠状病毒肺炎患者的临床疗效
World J Clin Cases. 2020 Sep 6;8(17):3763-3773. doi: 10.12998/wjcc.v8.i17.3763.
4
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.托珠单抗治疗重症新型冠状病毒肺炎住院患者的疗效：一项病例对照队列研究。
Pharmaceuticals (Basel). 2020 Oct 17;13(10):317. doi: 10.3390/ph13100317.
5
Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series.托珠单抗的早期使用可能预防部分新冠患者的临床病情恶化：病例系列研究
Cureus. 2020 Jul 14;12(7):e9187. doi: 10.7759/cureus.9187.
6
Tocilizumab and COVID-19.托珠单抗与新型冠状病毒肺炎
Indian J Crit Care Med. 2020 Sep;24(9):741-743. doi: 10.5005/jp-journals-10071-23608.
引用本文的文献
1
Outcomes of SARS-CoV-2 infection in patients under treatment with pharmacological immunosuppression. A Swiss cohort study.接受药物免疫抑制治疗患者的新冠病毒感染结局。一项瑞士队列研究。
Arch Med Sci. 2022 Aug 3;21(3):845-851. doi: 10.5114/aoms/152340. eCollection 2025.
2
Translatability scoring in prospective and retrospective COVID drug development cases.前瞻性和回顾性 COVID 药物开发病例中的可翻译性评分。
Eur J Clin Pharmacol. 2023 Aug;79(8):1051-1071. doi: 10.1007/s00228-023-03517-0. Epub 2023 Jun 6.
3
Efficacy and harms of convalescent plasma for treatment of hospitalized COVID-19 patients: a systematic review and meta-analysis.康复期血浆治疗住院COVID-19患者的疗效与危害：一项系统评价与荟萃分析
Arch Med Sci. 2021 Feb 18;17(5):1251-1261. doi: 10.5114/aoms/132492. eCollection 2021.
4
It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?是时候在合适的时间窗内基于新冠病毒感染的病理生理学考虑一种抗炎疗法了吗？
Arch Med Sci. 2021 Feb 26;17(2):546-550. doi: 10.5114/aoms/130647. eCollection 2021.
本文引用的文献
1
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.接受生物改善病情抗风湿药（bDMARDs）和靶向合成改善病情抗风湿药（tsDMARDs）治疗的患者中COVID-19的易感性和严重程度：一项基于人群的研究。
Ann Rheum Dis. 2020 Jul;79(7):986-988. doi: 10.1136/annrheumdis-2020-217903. Epub 2020 May 28.
2
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.COVID-19 患者与风湿病患者的临床特征和结局：来自美国“热点地区”的一项比较队列研究。
Ann Rheum Dis. 2020 Sep;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888. Epub 2020 May 26.
3
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
4
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
5
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?我们能否使用白细胞介素 6（IL-6）阻断剂治疗 2019 冠状病毒病（COVID-19）引起的细胞因子释放综合征（CRS）？
J Autoimmun. 2020 Jul;111:102452. doi: 10.1016/j.jaut.2020.102452. Epub 2020 Apr 10.
6
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
7
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
8
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
Zotero 插件